Drugs & Aging

, Volume 30, Issue 7, pp 561–568

Polypharmacy and Potentially Inappropriate Medication in the Adult, Community-Dwelling Population in Switzerland

  • Eva Blozik
  • Roland Rapold
  • Jan von Overbeck
  • Oliver Reich
Original Research Article

Abstract

Background

Polypharmacy and potentially inappropriate medication (PIM) are associated with adverse outcomes such as hospitalization, loss of productivity, and death.

Objective

This study evaluates the prevalence of polypharmacy and PIM in the adult community-dwelling population in Switzerland.

Methods

The analysis is done based on claims data from the largest health insurance in Switzerland. We calculated the number of medications submitted for reimbursement, the proportion of persons with polypharmacy, and the proportion of persons receiving PIM according to the 2003 Beers criteria and the PRISCUS list. Additionally, we estimated cost for medications and PIM, and identified the most prevalent groups of PIM according to the Anatomical Therapeutic Chemical Classification System (ATC).

Results

17 % of the adult community-dwelling population in Switzerland received 5 or more medications which is one of the common definitions of polypharmacy, and over 21 % of adults aged more than 65 years had a PIM according to 2003 Beers criteria or the PRISCUS list. The most prevalent classes of PIM were psycholeptics, sex hormones, psychoanaleptics, and antiinflammatory drugs.

Conclusion

Although the present study has a number of limitations, we conclude that the prevalence of polypharmacy and PIM in Switzerland is high. A broad spectrum of interventions on the individual level as well as on the population level is urgently needed.

Supplementary material

40266_2013_73_MOESM1_ESM.docx (119 kb)
Supplementary material 1 (DOCX 119 kb)
40266_2013_73_MOESM2_ESM.docx (118 kb)
Supplementary material 2 (DOCX 118 kb)

References

  1. 1.
    World Health Organization, Medicines: safety of medicines—adverse drug reactions, Fact sheet No 293 [online]. 2008. http://www.who.int/mediacentre/factsheets/fs293/en/index.html. Accessed 04 Oct 2012.
  2. 2.
    Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet. 2000;356(9237):1255–9.PubMedCrossRefGoogle Scholar
  3. 3.
    Pirmohamed M, James S, Meakin S, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ. 2004;329(7456):15–9.PubMedCrossRefGoogle Scholar
  4. 4.
    Albert SM, Colombi A, Hanlon J. Potentially inappropriate medications and risk of hospitalization in retirees: analysis of a US retiree health claims database. Drugs Aging. 2010;27(5):407–15.PubMedCrossRefGoogle Scholar
  5. 5.
    Ruggiero C, Dell‘Aquila G, Gasperini B, et al. Potentially inappropriate drug prescriptions and risk of hospitalization among older, Italian, nursing home residents: the ULISSE project. Drugs Aging. 2010;27(9):747–58.PubMedCrossRefGoogle Scholar
  6. 6.
    Klarin I, Wimo A, Fastbom J. The association of inappropriate drug use with hospitalisation and mortality: a population-based study of the very old. Drugs Aging. 2005;22(1):69–82.PubMedCrossRefGoogle Scholar
  7. 7.
    Fulton MM, Allen ER. Polypharmacy in the elderly: a literature review. J Am Acad Nurse Pract. 2005;17(4):123–32.PubMedCrossRefGoogle Scholar
  8. 8.
    Goldberg RM, Mabee J, Chan L, Wong S. Drug–drug and drug–disease interactions in the emergency department: analysis of a high-risk population. Am J Emerg Med. 1996;14(5):447–50.PubMedCrossRefGoogle Scholar
  9. 9.
    Beers MH. Explicit criteria for determining potentially inappropriate medication use by the elderly. Arch Intern Med. 1997;157(14):1531–6.PubMedCrossRefGoogle Scholar
  10. 10.
    Fick DM, Cooper JW, Wade WE, Waller JL, Maclean JR, Beers MH. Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts. Arch Intern Med. 2003;163(22):2716–24.PubMedCrossRefGoogle Scholar
  11. 11.
    American Geriatrics Society 2012 Beers Criteria Update Expert Panel. American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2012;60(4):616–31.CrossRefGoogle Scholar
  12. 12.
    McLeod PJ, Huang AR, Tamblyn RM, Gayton DC. Defining inappropriate practices in prescribing for elderly people: a national consensus panel. CMAJ. 1997;156(3):385–91.PubMedGoogle Scholar
  13. 13.
    Laroche ML, Charmes JP, Merle L. Potentially inappropriate medications in the elderly: a French consensus panel list. Eur J Clin Pharmacol. 2007;63(8):725–31.PubMedCrossRefGoogle Scholar
  14. 14.
    Holt S, Schmiedl S, Thurmann PA. Potentially inappropriate medications in the elderly: the PRISCUS list. Dtsch Arztebl Int. 2010;107(31–32):543–51.PubMedGoogle Scholar
  15. 15.
    Cahir C, Fahey T, Teeling M, Teljeur C, Feely J, Bennett K. Potentially inappropriate prescribing and cost outcomes for older people: a national population study. Br J Clin Pharmacol. 2010;69(5):543–52.PubMedCrossRefGoogle Scholar
  16. 16.
    Haider SI, Johnell K, Thorslund M, Fastbom J. Trends in polypharmacy and potential drug–drug interactions across educational groups in elderly patients in Sweden for the period 1992–2002. Int J Clin Pharmacol Therap. 2007;45(12):643–53.Google Scholar
  17. 17.
    Egger SS, Bachmann A, Hubmann N, Schlienger RG, Krähenbühl S. Prevalence of potentially inappropriate medication use in elderly patients: comparison between general medical and geriatric wards. Drugs Aging. 2006;23(10):823–37.PubMedCrossRefGoogle Scholar
  18. 18.
    Fialová D, Topinková E, Gambassi G, et al. Potentially inappropriate medication use among elderly home care patients in Europe. JAMA. 2005;293(11):1348–58.PubMedCrossRefGoogle Scholar
  19. 19.
    Hanlon JT, Schmader K, Ruby C, Weinberger M. Suboptimal prescribing in older inpatients and outpatients. J Am Geriatr Soc. 2001;49(2):200–9.PubMedCrossRefGoogle Scholar
  20. 20.
    Federal Office of Public Health. Bundesgesetz vom 18. März 1994 über die Krankenversicherung (KVG) [online]. http://www.admin.ch/ch/d/sr/c832_10.html. Accessed 04 Oct 2012.
  21. 21.
    Hertzlinger RE, Parsa-Parsi R. Consumer-driven health care: lessons from Switzerland. JAMA. 2004;292(10):1213–20.CrossRefGoogle Scholar
  22. 22.
    World Health Organization. ATC/ DDD Index 2012 [online]. http://www.whocc.no/atc_ddd_index/. Accessed 04 Oct 2012.
  23. 23.
    Papaioannou A, Kennedy CC, Dolovich L, Lau E, Adachi JD. Patient adherence to osteoporosis medications: problems, consequences and management strategies. Drugs Aging. 2007;24(1):37–55.PubMedCrossRefGoogle Scholar
  24. 24.
    Interpharma. Pharma-Markt Schweiz 2012 [online]. http://www.interpharma.ch/de/fakten-und-statistiken/Pharma-Markt-Schweiz.asp. Accessed 04 Oct 2012.
  25. 25.
    Rochon P, Gurwitz J. Prescribing for seniors: neither too much nor too little. JAMA. 1999;282(2):113–5.PubMedCrossRefGoogle Scholar
  26. 26.
    Hovstadius B, Hovstadius K, Astrand B, Petersson G. Increasing polypharmacy—an individual-based study of the Swedish population 2005–2008. BMC Clin Pharmacol. 2010;10:16.PubMedCrossRefGoogle Scholar
  27. 27.
    Slabaugh SL, Maio V, Templin M, Abouzaid S. Prevalence and risk of polypharmacy among the elderly in an outpatient setting: a retrospective cohort study in the Emilia-Romagna region, Italy. Drugs Aging. 2010;27(12):1019–28.PubMedCrossRefGoogle Scholar
  28. 28.
    Amann U, Schmedt N, Garbe E. Prescribing of potentially inappropriate medications for the elderly: an analysis based on the PRISCUS List. Dtsch Arztebl Int. 2012;109(5):69–75.PubMedGoogle Scholar
  29. 29.
    Felder S, Meier M, Schmitt H. Health care expenditure in the last months of life. J Health Econ. 2000;19(5):679–95.PubMedCrossRefGoogle Scholar
  30. 30.
    Werblow A, Felder S, Zweifel P. Population ageing and health care expenditure: a school of ‘red herrings’? Health Econ. 2007;16(10):1109–26.PubMedCrossRefGoogle Scholar
  31. 31.
    Gallagher PF, O’Connor MN, O’Mahony D. Prevention of potentially inappropriate prescribing for elderly patients: a randomized controlled trial using STOPP/START criteria. Clin Pharmacol Ther. 2011;89(6):845–54.PubMedCrossRefGoogle Scholar
  32. 32.
    Samsa GP, Hanlon JT, Schmader KE, et al. A summated score for the medication appropriateness index: development and assessment of clinimetric properties including content validity. J Clin Epidemiol. 1994;47(8):891–6.PubMedCrossRefGoogle Scholar
  33. 33.
    Organisation for Economic Co-operation and Development. OECD Reviews of Health Systems—Switzerland [online]. http://www.oecd.org/health/healthpoliciesanddata/oecdreviewsofhealthsystems-switzerland.htm. Accessed 04 Oct 2012.

Copyright information

© Springer International Publishing Switzerland 2013

Authors and Affiliations

  • Eva Blozik
    • 1
    • 2
  • Roland Rapold
    • 3
  • Jan von Overbeck
    • 1
  • Oliver Reich
    • 3
  1. 1.Swiss Center for Telemedicine MedgateBaselSwitzerland
  2. 2.Department of Primary Medical CareUniversity Medical Center Hamburg-EppendorfHamburgGermany
  3. 3.Department of Health SciencesHelsana GroupZurichSwitzerland

Personalised recommendations